Xbiotech Inc (NASDAQ:XBIT) had a decrease of 5.26% in short interest. XBIT’s SI was 1.65 million shares in December as released by FINRA. Its down 5.26% from 1.74 million shares previously. With 23,200 avg volume, 71 days are for Xbiotech Inc (NASDAQ:XBIT)’s short sellers to cover XBIT’s short positions. The SI to Xbiotech Inc’s float is 8.38%. The stock increased 0.60% or $0.03 during the last trading session, reaching $4.99. About 90,018 shares traded or 6.32% up from the average. XBiotech Inc. (NASDAQ:XBIT) has declined 7.38% since December 29, 2017 and is downtrending. It has underperformed by 7.38% the S&P500. Some Historical XBIT News: 16/04/2018 – XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology; 02/04/2018 – XBIOTECH INC – HAS OBTAINED AN EXCLUSIVE, WORLDWIDE LICENSE FROM CT ATLANTIC AG; 16/04/2018 – XBIOTECH INC – CONDUCTING FINAL PREPARATIONS FOR STUDY LAUNCH INCLUDING FIRST CLINICAL SITE INITIATION SCHEDULED LATER THIS MONTH; 02/04/2018 – XBIOTECH – WILL USE ITS TECHNOLOGY TO ADVANCE DEVELOPMENT OF TRUE HUMAN(TM )ANTI-NY-ESO-1 MONOCLONAL ANTIBODY, 12D7; 02/04/2018 – XBIOTECH IN-LICENSES ANTI-NY-ESO-1 ANTIBODY FROM CT ATLANTIC; 02/04/2018 XBiotech In-licenses Anti-NY-ESO-1 Antibody Targeting Advanced Cancer; 20/04/2018 – DJ XBiotech Inc, Inst Holders, 1Q 2018 (XBIT); 16/04/2018 – XBIOTECH INC – UPCOMING PHASE 2 CLINICAL STUDIES IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (AD) AND HIDRADENITIS SUPPURATIVA (HS); 16/04/2018 – XBIOTECH INC – CO WOULD EVALUATE A NEW SUBCUTANEOUS FORMULATION OF CO’S TRUE HUMAN MONOCLONAL ANTIBODY, MABP1, IN TWO SEPARATE PHASE 2 STUDIES; 22/05/2018 – XBiotech Announces First Patient in Phase 2 Study Evaluating MABp1 in Patients with Atopic Dermatitis
Tekla Capital Management Llc increased Edwards Lifesciences Corporation (EW) stake by 15.72% reported in 2018Q3 SEC filing. Tekla Capital Management Llc acquired 10,421 shares as Edwards Lifesciences Corporation (EW)’s stock rose 13.75%. The Tekla Capital Management Llc holds 76,696 shares with $13.35 million value, up from 66,275 last quarter. Edwards Lifesciences Corporation now has $31.44B valuation. The stock increased 0.27% or $0.4 during the last trading session, reaching $150.41. About 846,311 shares traded. Edwards Lifesciences Corporation (NYSE:EW) has risen 37.86% since December 29, 2017 and is uptrending. It has outperformed by 37.86% the S&P500. Some Historical EW News: 24/04/2018 – Edwards Lifesciences 1Q Net $206.6M; 24/04/2018 – EDWARDS LIFESCIENCES – CONTINUES TO EXPECT THVT FY UNDERLYING SALES GROWTH RATE TO BE AT HIGHER END OF 11 PCT TO 15 PCT; 21/03/2018 – EDWARDS LIFESCIENCES – NOW EXPECTS THAT EUROPEAN LAUNCH OF SAPIEN 3 ULTRA SYSTEM WILL OCCUR LATER IN 2018; 01/05/2018 – EDWARDS LIFESCIENCES IN ACCELERATED SHARE BUYBACK PACT; 24/04/2018 – EDWARDS LIFESCIENCES 1Q ADJ. EPS $1.22, EST. $1.11; 20/04/2018 – DJ Edwards Lifesciences Corporation, Inst Holders, 1Q 2018 (EW); 24/04/2018 – Edwards Lifesciences Sees 2Q Adj EPS $1.05-Adj EPS $1.15; 24/04/2018 – Edwards Lifesciences 1Q EPS 96c; 21/03/2018 – Edwards Completes Enrollment In PARTNER 3 Low-Risk CT Sub-Study, Updates Timeline For SAPIEN 3 Ultra System Launch In Europe; 24/04/2018 – Edwards Lifesciences Raises 2018 View To Adj EPS $4.50-Adj EPS $4.70
More notable recent XBiotech Inc. (NASDAQ:XBIT) news were published by: Nasdaq.com which released: “Mid-Afternoon Market Update: Dow Up Over 600 Points; Immunomedics Shares Surge – Nasdaq” on December 26, 2018, also Globenewswire.com with their article: “XBiotech Announces Successful Completion of GMP Audit – GlobeNewswire” published on December 03, 2018, Nasdaq.com published: “Health Care Sector Update for 12/12/2018: XBIT, SGYP, NBIX, MRNS, JNJ, PFE, MRK, ABT, AMGN – Nasdaq” on December 12, 2018. More interesting news about XBiotech Inc. (NASDAQ:XBIT) were released by: Nasdaq.com and their article: “XBiotech Announces Publication of Post-Hoc Analysis for Phase III Colorectal Cancer Study – Nasdaq” published on December 13, 2018 as well as Nasdaq.com‘s news article titled: “XBiotech’s Results from Phase 2 Atopic Dermatitis Study Suggest New Drug to Treat Skin Disease – Nasdaq” with publication date: December 12, 2018.
XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company has market cap of $178.74 million. The companyÂ’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It currently has negative earnings. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases.
Tekla Capital Management Llc decreased Mckesson Corporation (NYSE:MCK) stake by 15,850 shares to 82,947 valued at $11.00 million in 2018Q3. It also reduced Centene Corporation (NYSE:CNC) stake by 17,950 shares and now owns 166,869 shares. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was reduced too.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.